Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Almirall S.A. Stock

Price
Target price
€8.39

€8.39

0.000%
-
0.000%
-
 
09:46 / Tradegate WKN: A0MU8Y / Symbol: LBTSF / Name: Almirall / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Almirall S.A. in the next few years
Wizard

Financial data and news for Almirall

sharewise wants to provide you with the best news and tools for Almirall, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology: https://mms.businesswire.com/media/20240218250953/en/2037911/5/Almirall_RandD_2.jpg
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology


Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to

BusinessWire_EN 
0 19.02.24
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business: https://mms.businesswire.com/media/20240218334003/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business


Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.


This press release features multimedia. View the full release

BusinessWire_EN 
0 19.02.24
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases: https://mms.businesswire.com/media/20231221296013/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases


Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics,

BusinessWire_EN 
0 21.12.23
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases


Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement

BusinessWire_EN 
0 13.03.24
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology


Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and

BusinessWire_EN 
0 12.12.23
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis


Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment

BusinessWire_EN 
0 17.11.23
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases


Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug

BusinessWire_EN 
0 14.11.23
Almirall’s Nine-month 2023 Results:: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall’s Nine-month 2023 Results:


Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.


Financial highlights (€ rounded million)


 


9M 2023


9M 2022

BusinessWire_EN 
0 09.11.23